OVERDOSE AND TREATMENT: In chronic asthma studies, Montelukast was administered at doses up to 200 mg/day to adult patients for 22 weeks and, in short-term studies, up to 900 mg/day to patients for approximately a week without clinically important adverse experiences. In postmarketing experience and clinical studies, most adults and children did not experience any toxicity following Montelukast doses as high as 1000 mg. The most common reported adverse effects were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. In a large pediatric case series, Montelukast ingestions of up to 536 mg resulted in minimal or no adverse events. Treatment is symptomatic and supportive.
Sign Out
